Company Profile

Organogenesis Inc
Profile last edited on: 11/2/22      CAGE: 4JB06      UEI: VKK3WXM4RCZ7

Business Identifier: Bio-active wound healing and soft tissue regeneration
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

85 Dan Road
Canton, MA 02021
   (781) 575-0775
Location: Single
Congr. District: 08
County: Norfolk

Public Profile

Spun out of MIT, Organogenesis, Inc. is a longtime established tissue engineering firm focused in regenerative medicine - designing, developing and manufactureing medical products containing living cells and/or natural connective tissue. The company specializes in soft tissue regeneration for use in the areas of bioactive wound healing and oral regeneration. Its products include Apligraf, a living cell-based product indicated for the treatment of venous leg ulcers and diabetic foot ulcers; and GINTUIT, an allogeneic cellularized scaffold product indicated for topical (non-submerged) application to a surgically created vascular wound bed in the treatment of mucogingival conditions in adults. Only minimally SBIR involved, during early years, firm had traded on AMEX (1986-2002) but went into bankruptcy. Re-emerged later and went public again on Nasdaq (Jan 2017). Briefly re-entered SBIR arena in the regenerative medicine space before outgrowing program employment requirements.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Over 50M
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2000 1 NIH $154,800
Project Title: Tissue Engineering to Create Living Epidermal Biosensors
1999 1 NIH $100,000
Project Title: Development of a Tissue-Engineered Vascular Graft
1991 1 NIH $50,000
Project Title: Construction of a human cornea in vitro

Key People / Management

  Geoff MacKay -- President and Chief Executive Officer

  Milka Bedikian -- Vice President, Global Marketing, Bioactive Wound Healing

  Eugene Bell -- Founder

  Steven Bernitz

  Patrick Bilbo -- Vice President, Regulatory

  Michael Catarina -- Director, Enterprise Management

  Gary S Gillheeney -- EVP, COO, CFO

  Gary S Gillheeny -- Executive Vice President, Chief Operating Officer, Chief Financial Officer, Trea

  Kate Giovino -- Director, Clinical Operations

  Nancy L Parenteau

  Zorina Pitkin -- Vice President, Quality Systems

  Pauline M Schwartz

  Susan Sullivan